Lv1
40 积分 2022-01-27 加入
Recent advances in trophoblast cell‐surface antigen 2 targeted therapy for solid tumors
5个月前
已完结
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs
8个月前
已完结
Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis
9个月前
已完结
Molecular classification of hormone receptor-positive HER2-negative breast cancer
11个月前
已完结
Molecular classification of hormone receptor-positive HER2-negative breast cancer
11个月前
已完结
[Chinese multidisciplinary expert consensus on combined immunotherapy for hepatocellular carcinoma(2023 version)]
1年前
已完结
Pembrolizumab for previously treated, microsatellite instability–high/mismatch repair–deficient advanced colorectal cancer: final analysis of KEYNOTE-164
1年前
已完结
OA03.06 CodeBreaK 100/101: First Report of Safety/Efficacy of Sotorasib in Combination with Pembrolizumab or Atezolizumab in Advanced KRAS p.G12C NSCLC
1年前
已完结
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study
1年前
已完结
Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study)
1年前
已完结
皖公网安备34019202002308
